Ken Song has done it again. A buyer has picked up his all-out effort to prove T cell engagers belong in autoimmune medicine.
Song, a biopharma veteran, has staked his firm’s existence on a single thesis: that T cell engagers can work in autoimmune disease. Song built his company around this conviction, and now a buyer is validating it — writing a check to find out if that conviction holds.
What does the buyer actually get? A founder-driven platform and a bet that autoimmune is the next frontier for T cell engager science. If Song is right, the buyer got early into a category-defining approach to autoimmune treatment. If he’s not, the price is steep for a thesis that still needs proof.
The buyer is doubling down rather than diversifying. The deal signals that the company sees T cell engagers as central to its autoimmune future, not a hedged side bet.
Deal close timing and asset-level terms weren’t disclosed.
Diana Kowalski